Advice

Following a full submission.

Ibandronic acid is accepted for use within NHS Scotland for the treatment of tumour-induced hypercalcaemia with or without metastases.

It has been shown to be a cost-effective option in reducing serum calcium in patients with hypercalcaemia of malignancy.

Download detailed advice27KB (PDF)

Download

Medicine details

Medicine name:
Ibandronic acid (Bondronat®)
SMC ID:
122/04
Indication:
Tumour-induced hypercalcaemia with or without metastases
Pharmaceutical company
Roche
BNF chapter
Endocrine system
Submission type
Full
Status
Accepted
Date advice published
11 October 2004